These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 11529279)

  • 61. Omalizumab: an update on efficacy and safety in moderate-to-severe allergic asthma.
    Chipps BE; Figliomeni M; Spector S
    Allergy Asthma Proc; 2012; 33(5):377-85. PubMed ID: 23026179
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Anti-IgE therapy with omalizumab in asthma and allergic rhinitis.
    Dodig S; Richter D; Cepelak I; Benko B
    Acta Pharm; 2005 Jun; 55(2):123-38. PubMed ID: 16179127
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Eosinophilic pneumonia in an asthmatic patient treated with omalizumab therapy: forme-fruste of Churg-Strauss syndrome?
    Cazzola M; Mura M; Segreti A; Mattei MA; Rogliani P
    Allergy; 2009 Sep; 64(9):1389-90. PubMed ID: 19392997
    [No Abstract]   [Full Text] [Related]  

  • 64. Anti-IgE and other new immunomodulation-based therapies for allergic asthma.
    Jonkers RE; van der Zee JS
    Neth J Med; 2005 Apr; 63(4):121-8. PubMed ID: 15869039
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Management of asthma with anti-immunoglobulin E: a review of clinical trials of omalizumab.
    Nowak D
    Respir Med; 2006 Nov; 100(11):1907-17. PubMed ID: 16949266
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Anti-IgE for asthma in inner-city children.
    Pavord ID; Bush A
    N Engl J Med; 2011 Jun; 364(26):2556-7; author reply 2557-8. PubMed ID: 21714664
    [No Abstract]   [Full Text] [Related]  

  • 67. Home therapy with subcutaneous anti-immunoglobulin-E antibody omalizumab in 25 patients with immunoglobulin-E-mediated (allergic) asthma.
    Liebhaber M; Dyer Z
    J Asthma; 2007 Apr; 44(3):195-6. PubMed ID: 17454337
    [No Abstract]   [Full Text] [Related]  

  • 68. Immunoglobulin E: role in asthma and allergic disease: lessons from the clinic.
    Owen CE
    Pharmacol Ther; 2007 Jan; 113(1):121-33. PubMed ID: 17000005
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Efficacy of omalizumab in eosinophilic chronic rhinosinusitis patients with asthma.
    Tajiri T; Matsumoto H; Hiraumi H; Ikeda H; Morita K; Izuhara K; Ono J; Ohta S; Ito I; Oguma T; Nakaji H; Inoue H; Iwata T; Nagasaki T; Kanemitsu Y; Ito J; Niimi A; Mishima M
    Ann Allergy Asthma Immunol; 2013 May; 110(5):387-8. PubMed ID: 23622013
    [No Abstract]   [Full Text] [Related]  

  • 70. Omalizumab treatment in a child with severe asthma and multiple steroid-induced morbidities.
    Rizk C; Ring A; Santucci S; MacLusky I; Karsh J; Yang WH
    Ann Allergy Asthma Immunol; 2012 Sep; 109(3):222-3. PubMed ID: 22920081
    [No Abstract]   [Full Text] [Related]  

  • 71. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma.
    Bousquet J; Cabrera P; Berkman N; Buhl R; Holgate S; Wenzel S; Fox H; Hedgecock S; Blogg M; Cioppa GD
    Allergy; 2005 Mar; 60(3):302-8. PubMed ID: 15679714
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Modeling the effects of omalizumab over 5 years among patients with moderate-to-severe persistent allergic asthma.
    Grossman HL; Schlender A; Alperin P; Stanley EL; Zhang J
    Curr Med Res Opin; 2010 Dec; 26(12):2779-93. PubMed ID: 21050061
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Anti-IgE in allergic asthma and rhinitis: an update.
    Morjaria JB; Gnanakumaran G; Babu KS
    Expert Opin Biol Ther; 2007 Nov; 7(11):1739-47. PubMed ID: 17961096
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Omalizumab protects against allergen- induced bronchoconstriction in allergic (immunoglobulin E-mediated) asthma.
    Zielen S; Lieb A; De La Motte S; Wagner F; de Monchy J; Fuhr R; Munzu C; Koehne-Voss S; Rivière GJ; Kaiser G; Erpenbeck VJ
    Int Arch Allergy Immunol; 2013; 160(1):102-10. PubMed ID: 22948442
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Asthma that is unresponsive to usual care.
    Chapman KR; McIvor A
    CMAJ; 2010 Jan; 182(1):45-52. PubMed ID: 19825927
    [No Abstract]   [Full Text] [Related]  

  • 76. Anti-IgE treatment, airway inflammation and remodelling in severe allergic asthma: current knowledge and future perspectives.
    Samitas K; Delimpoura V; Zervas E; Gaga M
    Eur Respir Rev; 2015 Dec; 24(138):594-601. PubMed ID: 26621973
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Aeroallergen sensitization in asthma: genetics, environment, and pathophysiology.
    Long A
    Allergy Asthma Proc; 2010; 31(2):89-95. PubMed ID: 20406590
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Omalizumab has a place in therapy for asthma disease management.
    Pesko LJ
    J Manag Care Pharm; 2009 Apr; 15(3):284-8. PubMed ID: 19326960
    [No Abstract]   [Full Text] [Related]  

  • 79. Omalizumab for childhood asthma.
    Warner JO
    Expert Rev Respir Med; 2010 Feb; 4(1):5-7. PubMed ID: 20387287
    [No Abstract]   [Full Text] [Related]  

  • 80. Innovative therapies for asthma: anti-IgE -- the future?
    Weinberger M
    Paediatr Respir Rev; 2004; 5 Suppl A():S115-8. PubMed ID: 14980255
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.